Cite
HARVARD Citation
Hurry, M. et al. (2016). Cost-effectiveness of ceritinib in patients previously treated with crizotinib in anaplastic lymphoma kinase positive (ALK+) non-small cell lung cancer in Canada. Journal of medical economics. pp. 936-944. [Online].